Hantz Financial Services, Inc. Mirum Pharmaceuticals, Inc. Transaction History

Hantz Financial Services, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Aug 06, 2024	SELL	$17.59 - $23.83 $263,199 - $356,568	-14,963 Reduced 99.97%	5 $0
Q3 2022 Aug 06, 2024	BUY	$19.98 - $29.44 $3,036 - $4,474	152 Added 1.03%	14,968 $314,000
Q2 2022 Aug 06, 2024	BUY	$18.42 - $27.5 $28,145 - $42,020	1,528 Added 11.5%	14,816 $288,000
Q1 2022 Aug 06, 2024	BUY	$15.5 - $23.93 $29,636 - $45,754	1,912 Added 16.81%	13,288 $293,000
Q4 2021 Aug 06, 2024	BUY	$13.05 - $19.35 $148,456 - $220,125	11,376 New	11,376 $181,000

190

54M

177K

167K

Ticker MIRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,751,700
Market Cap $1.64B
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...

Get notified when there are updates to the investment portfolio of Hantz Financial Services, Inc., based on Form 13F filings with the SEC.

Stay updated on Hantz Financial Services, Inc. with notifications on news.